Search research articles
Contact Us
Filters
Showing results (131-140 of 204) with videos related to
Page
of 21
Sort By:
The Journal of Antimicrobial Chemotherapy
|
February 16, 2023
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
Tawanda Gumbo, Shashikant Srivastava, Devyani Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges
Gesham Magombedze, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Antimicrobial Agents and Chemotherapy
|
March 22, 2022
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
Shashikant Srivastava, Gunavanthi D Boorgula, Jann-Yuan Wang, et al.
The Lancet. Respiratory Medicine
|
April 11, 2014
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Keertan Dheda, Tawanda Gumbo, Neel R Gandhi, et al.
Microbiology Spectrum
|
September 10, 2025
Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against <i>Mycobacterium abscessus</i>
Avneesh Shrivastava, Gunavanthi D Boorgula, Sanjay Singh, et al.
The Journal of Antimicrobial Chemotherapy
|
September 20, 2017
The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent
Devyani Deshpande, Shashikant Srivastava, Moti L Chapagain, et al.
The Journal of Antimicrobial Chemotherapy
|
December 16, 2014
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study
Hiwot Hiruy, Zoe Rogers, Chris Mbowane, et al.
Antimicrobial Agents and Chemotherapy
|
July 12, 2017
Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing
Sander P van Rijn, Shashikant Srivastava, Mireille A Wessels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
Paul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
International Journal of Audiology
|
November 20, 2019
Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis
Nazanin Ghafari, Richard Court, Maxwell Tawanda Chirehwa, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 204) with videos related to
Sort By:
Page
of 21
The Journal of Antimicrobial Chemotherapy
|
February 16, 2023
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
Tawanda Gumbo, Shashikant Srivastava, Devyani Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges
Gesham Magombedze, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Antimicrobial Agents and Chemotherapy
|
March 22, 2022
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
Shashikant Srivastava, Gunavanthi D Boorgula, Jann-Yuan Wang, et al.
The Lancet. Respiratory Medicine
|
April 11, 2014
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Keertan Dheda, Tawanda Gumbo, Neel R Gandhi, et al.
Microbiology Spectrum
|
September 10, 2025
Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against <i>Mycobacterium abscessus</i>
Avneesh Shrivastava, Gunavanthi D Boorgula, Sanjay Singh, et al.
The Journal of Antimicrobial Chemotherapy
|
September 20, 2017
The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent
Devyani Deshpande, Shashikant Srivastava, Moti L Chapagain, et al.
The Journal of Antimicrobial Chemotherapy
|
December 16, 2014
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study
Hiwot Hiruy, Zoe Rogers, Chris Mbowane, et al.
Antimicrobial Agents and Chemotherapy
|
July 12, 2017
Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing
Sander P van Rijn, Shashikant Srivastava, Mireille A Wessels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
Paul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
International Journal of Audiology
|
November 20, 2019
Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis
Nazanin Ghafari, Richard Court, Maxwell Tawanda Chirehwa, et al.
Page
of 21